modelC03DA02
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | PotassiumCanrenoate | |
| ATC code: | C03DA02 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 150 | mL/min |
| other parameters in model implementation | ||
Potassium canrenoate is a steroidal antimineralocorticoid drug used as a diuretic, particularly for the treatment of conditions such as heart failure, hypertension, and edema. It is a prodrug of canrenone and is mainly used in hospital settings, commonly administered intravenously. In some countries, its use has declined in favor of other diuretics and antimineralocorticoids but it remains available in several European countries.
Pharmacokinetics
Pharmacokinetic parameters estimated for intravenous administration in healthy adults; no published, peer-reviewed, quantitative pharmacokinetic dataset found for potassium canrenoate itself—parameters are based on secondary literature and properties of related compounds (canrenone, spironolactone).
References
Suyagh, M, et al., & McElnay, JC (2012). Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients. British journal of clinical pharmacology 74(5) 864–872. DOI:10.1111/j.1365-2125.2012.04257.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22376078
Suyagh, M, et al., & McElnay, JC (2013). Potassium canrenoate treatment in paediatric patients: a population pharmacokinetic study using novel dried blood spot sampling. Journal of hypertension 31(9) 1901–1908. DOI:10.1097/HJH.0b013e3283626994 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23846862
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)